CurrentCignaPolicy N/A

Fentanyl transdermal products drug quantity management

Defines quantity limits and coverage criteria for generic fentanyl transdermal systems for Cigna-administered health benefit plans, including retail (30-day) and home delivery (90-day) maximums and exception criteria for cancer-related pain.

Policy Summary

PayerCigna

PolicyFentanyl transdermal products drug quantity management

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateApr 2, 2025

Key ActionApprove quantity exceptions per criteria and, if approved, provide authorizations for one year.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

15Retail max per 30 days

45Home delivery max per 90 days

1 yearException approval duration

72 hrsStandard dosing interval

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General strengths (12–87.5 mcg/hr): Covered when the Drug Quantity Management rule is met (retail maximum 15 systems per 30 days; home delivery maximum 45 systems per 90 days). Approval of additional quantities is recommended only for patients with a diagnosis of cancer and pain severe enough to require daily, around-the-clock, long-term opioid treatment if the patient meets ONE of the listed criteria.retail <=15 per 30 days; home delivery <=45 per 90 days

No overrides recommended; patients requesting greater quantity due to dose up-titration should be referred to the next higher strength patch.

100 mcg/hr specific rule: If the patient requires a dose greater than 100 mcg/hr, approve the requested quantity for a 30-day supply at retail or a 90-day supply at home delivery.>100 mcg/hr allowed per 30/90-day supply

Explicit allowance for quantities when total dose requirement exceeds 100 mcg/hr.

Requests for fentanyl transdermal systems that do not meet the Drug Quantity Management limits or the listed exception criteria are considered not medically necessary. The Drug Quantity Management limits include a retail maximum of 15 systems per 30 days and a home delivery maximum of 45 systems per 90 days for the listed strengths; exceptions must meet the coverage criteria to be approved.

Exceptions that fall outside the specified cancer-related criteria or that exceed the stated quantity limits without meeting those criteria are considered not medically necessary. Approval of additional quantities is recommended only for patients with a diagnosis of cancer and severe, around-the-clock, long-term pain who meet the stated exception criteria.

Provider Actions and Requirements

Note

Quantity exceptions require criteria-based approval

All approvals are provided for 1 year in duration. The Drug Quantity Management rule is intended to prevent stockpiling, waste, and order-entry errors for fentanyl transdermal products. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the clinical criteria; failure to meet those criteria may result in denial of coverage.

Documentation Required

Documentation and review

Approval of additional quantities of fentanyl transdermal products is recommended only for patients with a diagnosis of cancer and pain severe enough to require daily, around-the-clock, long-term opioid treatment when the patient meets the stated clinical criteria. Coverage determinations must consider: (1) the terms of the applicable benefit plan document in effect on the date of service; (2) any applicable laws and regulations; (3) relevant collateral source materials including coverage policies; and (4) the specific facts of the particular situation. Each request will be reviewed on its own merits and medical directors may exercise clinical judgment.

Step Therapy

No overrides / up-titration guidance

No overrides are recommended for these fentanyl transdermal products. If a patient requires a greater quantity because of dose up-titration, refer the patient to the next higher-strength patch rather than overriding quantity limits.

Denial Risk

Denial trigger

If the Drug Quantity Management rule is not met at point of sale, the request will be evaluated against the clinical criteria; failure to meet the criteria may result in denial. Providers should ensure requests include required documentation and supported diagnosis codes to avoid denial as not covered.

Drug Quantity Management Limits

Retail quantity limit (30 days)

ProductFentanyl transdermal system (12, 25, 37.5, 50, 62.5, 75, 87.5 mcg/hr)

Retail maximum quantity15 systems per 30 days

ApplicabilityApplies to listed strengths except the 100 mcg/hr-specific rule

Home delivery quantity limit (90 days)

ProductFentanyl transdermal system (12, 25, 37.5, 50, 62.5, 75, 87.5 mcg/hr)

Home delivery maximum quantity45 systems per 90 days

ApplicabilityApplies to listed strengths except the 100 mcg/hr-specific rule

Special handling for >100 mcg/hr total requirement

ConditionPatient requires a dose greater than 100 mcg/hr total requirement

Approval actionApprove the requested quantity for a 30-day supply at retail or a 90-day supply at home delivery

NoteThis is an explicit allowance separate from the general Drug Quantity Management limits

Definitions

Opioid-tolerant — definition

DefinitionOpioid-tolerant patient

Clinical meaningRequires an extended treatment period with a daily opioid analgesic; alternatives inadequate

Dosing implicationTransdermal fentanyl indicated only for opioid-tolerant patients requiring around-the-clock long-term opioid treatment

Dosing intervalStandard interval is 72 hours (some patients may require 48-hour intervals)

Background

Fentanyl transdermal systems are indicated for management of severe, persistent pain in opioid-tolerant patients who require around-the-clock long‑term opioid treatment when alternatives are inadequate. The transdermal patch is dosed at an interval of approximately 72 hours (with some patients requiring a 48‑hour interval), and initial titration should avoid increases before 3 days and may require up to 6 days to reach equilibrium. For quantity approvals beyond standard Drug Quantity Management limits, the policy recommends exception approval only for cancer‑related pain meeting the specified criteria.

Revision History

2025-04-02Annual revision / review dateLatest

Policy reviewed (Annual Revision) with update to reflect existing quantity limits for home delivery; review date recorded as 04/02/2025.

2024-04-30Annual revision / review date

Policy reviewed (Annual Revision) with removal of Duragesic transdermal system (brand only) from the policy.

2023-04-24Annual revision / review date

Policy reviewed (Annual Revision); no criteria changes recorded.